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background:  Rivaroxaban lacks a specific reversal agent. Fifty units/kg of 4-factor prothrombin complex concentrate (PCC, Cofact®) completely 
reversed the anticoagulant effect of rivaroxaban in healthy subjects (Eerenberg, Circulation 2011;124:1573). We hypothesized that infusion with 
doses of 37.5 or 25 units/kg of PCC would be able to reverse the anticoagulant effect of rivaroxaban.
methods:  In a randomized, double blind, placebo-controlled study, 6 healthy volunteers taking rivaroxaban 15 mg twice daily, received either a 
single bolus of PCC 37.5 units/kg, PCC 25 units/kg or placebo, with a wash-out period of 18 days in between infusions. The primary outcome was the 
effect of PCC on measures of thrombin generation, e.g. endogenous thrombin potential (ETP), 15 minutes after infusion.
results: Fifteen minutes after infusion of 37.5 units/kg PCC, ETP increased from 47% ± 16% to 64% ± 22% (p=0.028). After infusion of 25 units/
kg PCC, ETP increased from 53% ± 11% to 59% ± 12% (p=0.142). The change in ETP with 37.5 units/kg PCC was significantly higher compared to 
placebo (p=0.041), but was not significantly different between 25 units/kg PCC and placebo (p=0.109). Furthermore, ETP levels were significantly 
different over time between PCC 37.5 units/kg and placebo (p=0.001) during 24 hours after infusion.
conclusions:  PCC in a dose of 37.5 units/kg significantly increases ETP in healthy volunteers treated with rivaroxaban. This study suggests that 
PCC has a dose dependent reversal effect on rivaroxaban.
 
